Double Blind Randomised Placebo Controlled Evaluation of Single and Multiple Oral Doses of ATX2417 in Man and Effect of Food
Phase of Trial: Phase I
Latest Information Update: 22 Jul 2016
At a glance
- Drugs ATX 2417 (Primary)
- Indications Asthma; Hypersensitivity
- Focus Adverse reactions; First in man
- Sponsors Atopix Therapeutics
- 12 Jul 2016 Status changed from recruiting to completed.
- 26 May 2015 According to ClinicalTrials.gov, treatment arms increased from 14 to 18; patient number changed from 56 to 72.
- 26 May 2015 Planned number of patients changed from 56 to 72 as reported by ClinicalTrials.gov